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Abstract 
In critical care tight control of glucose has been shown to lead to better clinical 
outcomes and reductions in length of stay. The need arises to develop new protocols for 
maintaining tight control of patients' glucose. The current hindrance to developing new 
protocols is the large amount of computational time and resources that are needed. This 
paper is based on finding fast analytical based methods for the insulin-glucose model. 
Exploiting the stmcture and partial solutions in a subset of the model was the key in 
finding accurate solutions to the full model. This successfully reduced the computing 
time compared to the numerical methods used currently by a factor of 6000 whilst 
introducing minimal enor. This will allow new protocols to be rapidly developed leading 
to better clinical outcomes for patients in critical care. 
Fast algorithms for model based therapeutics 
1 Introduction 
Tight control of glucose has gained significant importance in critical care after Van den 
Berghe et al. [1] showed that up to 45% reductions in mortality are possible. In [2,3], a 
glucose-insulin model was used to guide feed and insulin inputs for critical care patients 
and maintained tight blood sugar levels for trials of up to 12 hours long. However, to 
simplify the clinical application of the algorithm, a nutrition-insulin table protocol [ 4,5] 
was developed to mimic the model based algorithm of [2,3]. The trials in [ 4,5] represent 
the first model-based protocol to report a significant clinical outcome with a 30% 
mortality reduction, significantly higher APACHE scores and the tightest glucose control 
reported so far as compared to other studies [e.g. 6]. 
A critical part of the development of [ 4,5] was the creation of a virtual patient database 
and the implementation of virtual patient clinical trials to optimize the protocol before 
application on real patients. The virtual patient database represents a summary of the 
metabolic changes of patients in a cohort over the entire length of stay in the intensive 
care unit (ICU). The primary parameter used to represent a patients' metabolic status was 
insulin sensitivity ( S 1 ) which was made time varying, with changes over a one hour 
period, and was found from retrospective trials using an integral-based parameter 
identification method [7]. Shmter trials in [2,3] were also added to the database. In these 
trials ([2,3]) the S 1 profile was generated in real time using the algorithm of [7] and were 
used to predict patient response in the following hour, thus calculating the amount of 
insulin and reduction/addition of feed required to maintain blood glucose concentration in 
the 4-6 mmol/L band. 
The insulin sensitivity profiles obtained in the retrospective [7] and model-based glucose 
control trials [2,3] provide the means to cany out "virtual" clinical trials to test glucose 
control protocols. The process of creating a virtual patient cohort and then testing new 
protocols using the physiological model is referred to as "model-based therapeutics". 
This model-based therapeutics (MBT) approach led to the development of the SPRINT 
(Specialized Relative Insulin + Nutrition Tables) protocol that has been implemented in 
the Christchurch hospital ICU [ 4,5]. One key feature of the MBT approach is the close 
similarity between the probability density of the real and virtual clinical trials as shown in 
Figures 1 and 2. 
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Figure 1: Frequency distribution of real and virtual trials 
0.9 
0.8 
0.7 
.£ 
'6 Jll 0.6 
e 
~ 0.5 
> ~ 
"5 0.4 
E 
8 0.3 
0.2 
0.1 
I 
I 
5 
~ Model simulation- SPRj 
---- ICU data 
-- --
10 15 20 
Glucose concentration 
25 
Figure 2: Cumulative probability function of real and virtual trials. 
Figures 1 and 2 provide a strong motivation to further develop MBT technologies and 
initial successful results have been obtained in several other areas, including model based 
cardiac diagnosis [8-10], insulin sensitivity [11-12] agitation-sedation and lung 
ventilation. 
A fundamental element in the MBT approach is highly accurate, easily programmable, 
fast forward solutions to non-linear physiological models. Fast forward simulations are 
required to trial many therapeutic options to find the best treatment. Some initial work in 
a cardiac model has shown that with certain mathematical reformulation, significant 
speed increases are possible [13]. However, a major is that practical analytical solutions 
to most non-linear physiological models are very difficult to obtain and thus 
computationally intense numerical solvers are required. For example in the testing and 
development of the SPRINT protocol [ 4,5], each patient must be simulated at least 20 
times with random noise on the "measured data" to ensure the algorithm is robust to 
noise, which is a standard Monte-Carlo approach. Each patient involves on average, 
around 5 days or 120 hours of data, which after Monte-Carlo simulation amounts to a 
minimum of 2400 hours per patient. In practice, to obtain an accurate sample, up to 100 
Monte-Carlo simulations are done for each patient. The virtual database has now grown 
to 165 patients. This would conespond to 3,960,000 patient hours required to simulate a 
new protocol. 
The SPRINT protocol [ 4,5] has tended to slightly underfeed patients. Thus one new 
protocol would be to increase the overall feed of patients, while maintaining the same 
tight glucose control. Other potential protocols include minimizing the number of 
measurements required for general wards, developing a protocol for pediatrics and 
improving the cun·ent SPRINT protocol. 
To get an idea of the computation time required, a standard ODE solver in MATLAB 
takes 0.5656s to simulate one patient hour on a laptop with a 1.73GHz processor. This 
would amount to 24days of simulation or alternately 2.4 days with 10 computers. 
However as many more patients are added, greater numbers of protocols are tested; and 
potentially more dynamics are added to the glucose-insulin model, (e.g. more detailed 
feed model); significant computing time and resources would be required. This would 
limit the number of patients and protocols that could be tested, potentially hindering 
research outcomes. 
The glucose control protocols only require a simulated measurement at most on the hour, 
yet numerical ODE solvers compute the glucose at every time step throughout the hour 
[e.g. Maki, 2006]. In other words a large percentage of computation is spent calculating 
glucose values that are not used. 
The non-linear glucose-insulin model equation [3] however has no direct analytical 
solution. The approach in this research, is to form partial analytical solutions to a subset 
of the model in terms of simpler approximating functions that are valid within known 
physiological bounds. These simpler functions then enable an analytical solution to the 
whole model. In other words, the approach is to reformulate and tailor solutions to the 
specific application required. With careful construction and the use of both elementary 
and advanced mathematical solutions to differential equations, it is shown that an 
approximate, but highly accurate analytical solution can be found to the full non-linear 
glucose insulin model. This solution dramatically increases the forward simulation speed 
of the model, thus allowing the rapid development of new protocols aimed to improve 
patient outcome. 
The solution is compared rigorously to the numerical solution over many virtual 
simulations and is found to be highly accurate. 
An example of the application of the method is given by testing a protocol aimed to 
increase the overall feed to patients. 
2 Methodology 
2.1 Model of glucose and insulin kinetics 
The model of glucose and insulin kinetics [3] used to mn virtual trials is loosely based on 
Bergman's minimal model with additional non-linear terms and a time varying insulin 
sensitivity S 1 = S 1 (t), defined as follows: 
Q = -kQ+ki 
i=- ni +uex 
1 + a 11 V 
P( ) _ p (P( ) p ) -k"(t-t;) f; < t < ti+I - i+I + t; - i+I e 
where: 
= {k ~'"} {f ?;+1 < P(t;) 
kp - ( )' kpr if P;+l > P f; 
(1) 
(2) 
(3) 
(4) 
Geq is the equilibrium plasma glucose concentration and G is the plasma glucose 
concentration above Geq. The exogenous feed input rate is denoted P(t); l(t) is the 
plasma insulin resulting from exogenous insulin input u eJt); Q(t) is the concentration of 
insulin bounded to interstitial sites; k accounts for the effective life of insulin in the 
system. Patient endogenous glucose clearance and insulin sensitivity are p g and S 1 
respectively; V is the insulin distribution volume and n is the constant first order decay 
rate for insulin from plasma. Michaelis-Menten functions are used to model saturation, 
with a 1 used for the saturation of insulin disappearance, and aG for the saturation of 
insulin-dependent glucose clearance; k pr and k pd are the effective half lives for 
increasing and decreasing feed rates where P; and ?;+1 are the steps in enteral glucose 
feed rates. 
The parameters k, n, a 1 , V, k pd and k pr are held at population values and G eq is 
estimated from the mean glucose concentration over the patients stay [3,7]. The 
parameters S 1 and p 8 are patient specific. Note that for simplicity the model of equation 
(1) is reformulated by replacing G by Gtntal - Geq in Equation (1): 
(5) 
2.2 Virtual patient cohort 
For this research, 17 uncontrolled patients were used from the study in[7], and 51 
controlled patients on the SPRINT system [ 4,5] to form the virtual patient cohort. The 
patients physiology were summarized by their insulin sensitivity S 1 (t) as well as glucose 
effectiveness p 
8 
(t), and were obtained using the integral based parameter identification 
method[7]. Given nutritional and insulin inputs, and a patients S 1 (t) and p 8 (t) profile, 
equations (2)-(5) can then be solved, which is refened to as a "virtual trial". Different 
protocols can be applied on a specific patient by changing the nutritional and insulin 
inputs while keeping the S 1 (t) and p 8 (t) profile the same. In other words potential 
improvements to the current protocol can be tested without requiring a full intervention 
clinical trial. This approach ensures that before any new clinical trial, a protocol would 
have been shown to be "safe" and is optimized for the best possible patient outcome. 
2.3 Plasma Insulin response 
In the SPRINT protocol [ 4,5], a bolus of insulin is given on the hour with a lower 
background infusion given throughout the hour. The magnitude of the bolus depends on 
the patients' physiology and what is required in the protocol. For example, the cunent 
protocol (SPRINT) maintains a glucose concentration between 4 and 7 mmol/L. The 
insulin bolus is modeled as a constant infusion over one minute. Figure 3 shows a typical 
patient response over one hour to both a bolus and constant infusion of insulin. 
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Figure 3: Typical patient Insulin response to a 
bolus and background infusion. 
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Figure 3 is obtained by solving equation (3) numerically given the parameters: 
{
2400mU 
n = 0.16, a 1 = 0.0017, v = 12, u . = mUin, e.> 117 
17-. 
mm 
and the initial condition I ( 0) = 17 m U . 
L 
The goal in this section is to find an accurate closed form analytical expression for I(t) 
that is very fast to evaluate. Another important requirement on the expression for l(t) is 
that it is easily integrable and thus can be put into equation (2) to obtain a simple 
analytical solution for Q(t). 
However, the major problem with finding a relatively simple solution to equation (3) is 
the saturation term; -n ·l(t )/(1 +a, · l(t )) . Therefore it was initially investigated to see 
what effect the assumption a, = 0 has on results. Figure 4 overlays the solution of 
Equation (3) with a, = 0.0017 and a, = 0. 
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Figure 4: Plasma Insulin response with and without 
saturation 
The enor between the two curves in figure 4 is significant, especially from 1 to 30 
minutes where the mean relative error is 14.8%. However it is the effect on the glucose 
concentration which is the most impmtant. To test this one patient was simulated with 
and without the saturation term. Figures 5 and 6 show two examples of the effect that the 
saturation term has on the glucose concentration. In Figure 5 only an insulin bolus is 
given, and the effect of the saturation term is very prominent producing a relative mean 
error of 14.92%. The error also propagates through the trial. In Figure 6 the glucose 
response is to a background infusion of insulin only, and the effect of the saturation is far 
less than Figure 5, producing a mean relative enor of 1.91 %. Since, the SPRINT protocol 
uses bolus insulin inputs the saturation term cannot be ignored. 
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Figure 5: Glucose response of patient 87 (#REF) to insulin bolus only. 
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Figure 6: Glucose response of patient 87 (#REF) to background infusion only. 
With a 1 ;t: 0 in Equation (3) an analytical solution was found in MAPLE in the period 
from 1 to 60 where there is no bolus and only a background constant infusion. The 
solution could not be extended to include the first minute and thus could not handle the 
sudden jump in uex of Equation (3) due to the bolus. One option here would be to 
numerically solve equation (3) over 1 minute, but this typically requires a step size of less 
than 0.01 for sufficient accuracy, potentially slowing the algorithm down. 
However, as can be seen in figure 3 the plasma insulin concentration in the first minute is 
close to linear. Thus one approach to speed up the solution to I(t) in the first minute 
would be to assume a general linear function for I(t) defined as follows: 
I(t)=I(O)+a0 ·t , O~t~l (6) 
Where the parameter a0 is found so that equation (6) satisfies equation (3) at t = 1. 
To find a0 , both sides of Equation (3) are multiplied by (1 + a,I(t )) and is thus written in 
the following form: 
(1 + aJ(t ))i(t )+ nl(t)-~(1 + aJ(t)) = 0 (7) 
v 
where uex = ub is the magnitude of the bolus. 
Substituting equation (6) into Equation (7) and putting t = 1 yields: 
a1 ·a0 2 +(1+u"~a1 +a1 ·I(O)+n}a0 +n·I(O)-~ _u"·a~·l(O)=O (8) 
Equation (8) is a quadratic equation in a0 and has two roots: 
-b± .Jb2 -4 ·a· c ~= ~ 2·a 
where: 
a~ a, b ~ (I+ u, ~a, +a, ·l(O)+n). c ~ (n·/(0)- 'j -u, ·a~·l(O)) (10) 
Through extensive numerical simulation with physiological bounds on ub and 1(0), the 
root that gave the correct insulin value on forward simulation was found to consistently 
be: 
(11) 
where a,b,c are given In equation (10). 
The approach of Equations (6)-(11) is referred to as a differential method as it involves 
differentiating the model curve approximation. An example of the differential method is 
given in Table 1 below, which shows that the approximated I(t) significantly 
undershoots the true I (t) . 
T bl 1 C a e ompanson o f d'ff h d f 1 erent met o s o r aQQroximatmg msu m response 
Approximation Method Differential Integral 
Linear 172.5983236 179.8588913 
Parabolic 180.7999280 180.0200918 
Actual 180.00533936 N/A 
An alternative approach is to integrate equation (7) first from 0 to t then substitute 
equation (6). Integrating and expanding Equation (7) yields: 
! i (t )dt + a I ! I (t) · i (t }it + n ! I (t )dt - u b ~a I ! I (t )dt - ~ ! dt = 0 (12) 
I 
Replacing I(t)·i(t) with(~ I(tY) and collecting terms: 
I 
!i(t}it+ai !(~I(t)2 ) dt+(n-ub~ai )!I(t)dt-~~ !dt=O (13) 
which after further simplification yields: 
I (t)- I ( 0) + i (I (t Y - I ( 0 Y )+ ( n - u b ~a I } ! I (t )dt - ~ · t = 0 (14) 
In a similar way to equation (8), equation (6) is then substituted into the integral 
formulation of equation (14) with t = 1 , giving a quadratic equation in a0 defined as 
follows: 
1 2 ( I(O) n ubai 1) I(O) ubaii(O) ub_ 0 -a a + a +----+ a +n - ---2 I 0 I 2 2V 0 v v (15) 
After simulation, the correct root a0 of Equation (15) is found to be: 
a0 =max [-b±-Jb
2 
-4·a·cJ 
2·a 
(16) 
where: 
_ 1 b _ ( I(o) n ubai 1) d _ I(o) ubaii(o) ub a--a - a +----+ an e-n - -2 I' I 2 2V v v (17) 
Equations (12)-(17) is refened to as an integral method and the results of an example are 
given in Table 1, which shows a significantly more accurate approximation to I(t) than 
the differential method of equations (6)-(11) This was also found to be the case with 
many simulations of different bolus sizes and initial conditions, showing that the integral 
method is significantly more accurate than the differential method. These results could be 
explained by the well known fact that differentiation in general magnifies noise/error 
where integrals are more robust [14]. 
Even though the linear function in Equation (6) gave a good approximation to the 
solution for the integral method, in practice, equations (2)-(5) must be solved with a 
potentially different S 1 , p g, uex and P(t) every hour. Thus an error in one hour will 
cany over to an error in the next hour and so on. To reduce this propagation of enor, the 
slight non-linearity in the first minute of I(t) is modeled by adding a parabolic term to 
equation (6) and setting a0 = i(o), yielding: 
I(t)=I(O)+i(O)·t+a1 ·t2 (18) 
For the integral method, substituting equation (18) into 
quadratic equation, which has the following correct root: 
equation (14) also yields a 
(
-b±-Jb
2 
-4·a·c] a1 =max -------2·a (19) 
where: 
a=!!!___ ,b = 1+~-~+ a,(I(o)+ i(o)), 
2 3 3·V 
c ~ i(o)+ a; (1(0)+ (I(o)+ i(o))' )-~ +-"':' )(1(0)+ i~)) (20) 
The derivative method is similar to equations (6)-(11) so the details are omitted. 
Table 1 shows that for a parabolic approximation both methods improve the result but the 
integral method is significantly more accurate. Note that given the a1 from the integral 
method of Equations (18)-(20), a cubic term could be added, or a quartic term and so on 
to improve accuracy, but the parabolic approximation was found to be sufficiently 
accurate. 
2.4 Insulin approximation after first minute 
Using the MAPLE software package the solution of Equation (3) is written in the form: 
() (b1 -Jv-LambertW(t)) It = b0e +b2 (21) 
where: 
_uex b _ (u,-I(I)n+I(I)a,u,) __ (-n+u,aJ2 
U I - ' 0 - ' 111 -V -n+u1a 1 n 
b _ u/a/ -2nu 1a 1 -I(I)a/u, +n
2 
-u 1a 1 +l(I)a,n u, and 
' I- ' b2 =---'---
11 -n+u1a 1 
t = a,(-n+u,aJb
0
e(",t+b1) (22) 
n 
The LambertW function is defined as the solution y = LambertW(t) to the equation: 
y·e-"=t (23) 
Equation (21) can be further simplified as follows: 
. I{t) = bae-lambertW(l}eb'-"'t + b2 (24) 
From Equation (23); 
e-lamhertw(l) = e-y = ~ = lambe~tW(t) (25) 
t t 
(26) 
(27) 
where: 
(28) 
F. 7 h h f · ( lambertW(t)) h f f 1 60 · h h 1gure s ows t e unctiOn B" t overt e range o t rom to w1t t e 
input of: 1(0) = 140, u 1 = 3. To satisfy the criteria that I(t) function is integrable and 
that the resulting Equation (2) can be solved easily. 
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0 t 
The curve in Figure 7 is represented by a linear function: 
Bo lambertW(t) :::::: Bl + B2t (29) 
t 
where B1 and B2 are arbitrary constants. Substituting into Equation (27) yields: 
I(t)=(B1 +B2t)e-1111 +b2 (30) 
= b2 + B1e- 1111 + B2te-1111 (31) 
For further accuracy the linear term bi is added to take up some of the modeling error 
introduced in the approximation of Equation (29): 
I(t)- b + b t + B e-1111 + B te-1111 (32) 
- 2 3 I 2 
In Equation (32) the parameters; B1 , B2 , b2 , b3 are initially unknown constants that are 
detetmined by fitting Equation (32) to predefined points of the analytical solution I(t) 
defined in Equations (21)-(22). Importantly, Equation (32) is easily integrated, so is 
suitable for developing an analytical solution for Q(t) in equation (2). Note that 
polynomial only approximations to Equation (21) were not suitable as they required too 
many terms (up to order 10) for sufficient accuracy, significantly slowing down the 
algorithm. 
To uniquely determine the 4 constants in equation (32) at least 4 values of 1(t) in 
equation (21) would be required. However, evaluating Equation (21) was found to be 
very slow, predominantly due to the LambertW function which requires a numerical 
iterative solution y to equation (23) for every evaluation. The LambertW function was 
thus reformulated to speed up evaluation as follows: 
Approximating ye-" by e"1." + c2 in equation (23) yields: 
e"0 +c2 = t 
Equation (33) is easily solved for y : 
y = lambertW(t )= d1 ln(t + d2 ) 
(33) 
(34) 
1 
where : d1 =- and d 2 = -c2 (34a) 
cl 
The approximation of equation (34) introduces modeling error, so a third degree 
polynomial is added. This gives the final approximated LambertW function as: 
LambertW(t) = a1 ·ln(t + aJ+ a3 + a4 • t +as · t 2 + a6 • t 3 (35) 
Note that without the d1 ln(t + d 2 ) term, very high order polynomials (> 10) are required 
for a similar accuracy, significantly increasing the number of multiplications/divisions: 
The parameters a1 , a2 , a3 , a4 , as, a 6 best approximating the LambertW function, are 
found for the range 0 ~ t ~ 50 . The range is more than enough for representing the 
required evaluation of the LambertW function in equation (21) which is typically 
O~t~16. 
Using equations (21)-(22) and (35) the plasma insulin concentration can be calculated 
throughout the hour. This information is used to find the solution to equation (32) so that 
a sufficiently integrable function is available to solve equation (3) for the interstitial 
insulin compartment. The plasma insulin concentration is found using equations (21)-(22) 
at 3 points through the hour: 1(10 ), 1(40), 1(60). Also using the concentration 1(1) 
obtained from equations (17)-(19). These four points are used to set up a set of linear 
equations: 
1 1 e-n e -II b2 1(1) 
1 10 e-JOn lOe-10" b3 1(10) (36) = 
1(40) 1 40 e-4on 40e-40n BJ 
1 60 e-60n 60e-60n B2 1(60) 
The solution of Equation (35) gives the coefficients of equation (32). 
2.5 Interstitial Insulin compartment 
The interstitial insulin compartment represents insulin that has been bounded to the 
interstitial sites [ 15] which can be utilized over time. Figure 6 shows a typical interstitial 
insulin response to an exogenous insulin bolus and background infusion. 
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The curve in figure 6 is obtained by numerically solving equations (2) and (3) with 
k = 0.0099 and plotting Q(t). An analytical solution for Q(t) is constructed in two parts. 
In the first part, the parabolic approximation of the plasma insulin response in the first 
minute given by equations ( 18)-(20) are substituted into equation (2) which yields: 
Q(t)=-k·Q(t)+k·(I(o)+j(o)·t+a1 ·t 2 ), o::;t::;1 (37) 
Equation (36) is then solved in MAPLE producing an analytical solution over the first 
minute defined as follows: 
Q{t)~ I(O)+ i(o)·t _ i~o) +a, ·t' 2·:, ·t + 2~':' _ (I(o)·k'- i(o). k +~;a, -Q{O)· k' ).e-'' (38) 
The solution for the rest of the hour is obtained by substituting equation 
equation (2) and solving in MAPLE with the initial condition Q(1)= Q1 : 
Q(t) =(b0k -b/ct-b1J(1-ek(I-r} )+ k(Jl + b3(t(k -n)-l)Je-m 
k k-n (k-n)2 
( k(b2(k-n)+b3(k-n-l))J k(I-r)-11 Q k(I-r) - 3 2 e + 1e k· - 2kn+ n 
The value of Q1 in Equation (39) is found by setting t = 1 in equation (38). 
(32) into 
(39) 
Equation (39) can then be evaluated to find the interstitial insulin concentration 
throughout the hour. 
2.6 Glucose response 
Given a closed form, integral expression for Q (t) the glucose Equation (1) can be solved 
by an integrating factor so that it can be solved as shown below: 
Equation (5) is rewritten in the form: 
Growl+ Q (t )Gtotal = d0 + d 1e -kpt 
where: 
-() Q(t) -kpt () Q t =pa+S1 () andd0 +d1e =pgGeq+Pt 1+a1Q t 
The integrating factor is introduced as: 
(.) 
r'o(t)dt 
JL t = e10 
'() -( )er'o(t)dt JLf=Qt Jo 
(40) 
(41) 
(42) 
(43) 
However currently even though the Q (t) is integrable a cubic polynomial is used as an 
approximation: 
Q(t)= fo + f 1t+ f 2t 2 + f~t 3 (44) 
The coefficients of equation (44) were found by evaluating Q(O), Q(20), Q(40) and 
Q ( 60), then setting up the set of equations: 
1 0 0 
1 20 202 
1 40 40 2 
1 60 602 
fo Q(O) 
f1 Q(20) 
= 
/ 2 Q(40) 
!3 Q(6o) 
Solving equation (45) gives the coefficients of equation (44). 
Substituting equation ( 44) into ( 42) gives: 
() 
f'to+N+ht 2+}313dt 
JL t = e10 
t2 t3 t4 
(45) 
(46) 
Jot+ Ji-+.r2-+ t3-
= e 2 3 4 (47) 
This integrating factor is used by multiplying Equation (40) by Equation (42) giving: 
JL(t )a total+ Q (t )JL(t )Gtotal = JL(t )(d a + d1 e -kpt) c 48) 
By making the substituting of Equation (43) yields: 
The term on the RHS of equation is recognized as the derivative of a product: 
(,u(t )· Gtotal (t ))' = ,u(t )·(do+ die -k,t) (50) 
Integrating both sides of equation (46) from 0 and t yields: 
!(,u(t)·Gtotal(t))'dt= !,u(t)·(d0 +die-k/~t (51) 
Giving: 
(52) 
Which can be reananged for Gtotal (t) as follows: 
G (t)= r(fd +d ·e-k,·r). ,u(r)t,+ Gtota1(0) 
total .h ~ o I ,u(t) r ,u(t) (53) 
The function inside the integral in equation (53) is not readily integrable due to the :i;] 
term. Similarly to equations (44)-(45) JI(t)= ,u((r)) is approximated with the cubic: 
J.lf 
JI(t)= go+ git + gzt2 + gi3 (54) 
This makes equation (53) integrable giving: 
Gtotal (t )= r ((do+ die -kl,r Xgo + giT + g2T2 + g3T3 )). dr (55) 
Evaluating the equation (55) yields: 
(56) 
3 Results 
3.1 Uncontrolled virtual patients 
In the retrospective trial of 17 ICU patients in [7] the patients were effectively 
uncontrolled due to insulin being administered "ad-hoc" by clinical staff using their own 
discretion and experience. The insulin sensitivity profiles obtained in [7] provided the 
means to carry out "virtual" clinical trials using the method explained in section 4 and 
also numerical simulation methods. Comparing the method in section 2 with the 
numerical simulation provides the metric to determine how robust and accurate the new 
method is. Figure 8 below shows both simulation methods of patient 87 from the ICU 
cohort. The absolute relative percentage error between the curves is 0.089% with the 90% 
confidence interval from 0.069% to 0.078%. 
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Figure 8: Numerical and analytical simulations of patient 87 
Table 1 below shows the statistics of the relative percentage enor between the numerical 
simulation and the method described in this paper, for the whole 17 patient cohort. The 
patients were simulated twice, one with only a background infusion of insulin input and 
the other with only bolus insulin input. Over the whole cohort the mean relative enor was 
found to be very small especially for simulation receiving insulin through background 
en·or. Whereas the mean relative enor for the simulation with only bolus insulin input, 
was found to be larger due to the saturation term in equation (3) effecting the insulin 
bolus input far more than the background infusion. 
r ·l:lble 2: Statistics of uncontrolled patient virtual trials 
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Lower Upper Lower Upper Lower Upper Lower 
Mean Median Median quartile quartile _g_uartile quartile 90%CI 90%CI 90%CI 
Infusion Bolus Infusion Bolus Infusion Infusion Bolus Bolus Infusion Infusion Bolus 
0.111 0.126 0.084 0.115 0.041 0.135 0.052 0.077 0.040 0.178 0.094 
0.089 0.229 0.078 0.169 0.486 0.106 0.211 0.053 0.069 0.078 0.132 
0.166 0.173 0.061 0.094 0.087 0.018 0.435 0.304 0.064 1.125 0.166 
0.112 0.359 0.072 0.277 0.079 0.306 0.181 0.244 0.096 0.059 0.024 
0.115 0.399 0.060 0.348 0.050 0.056 0.209 0.573 0.002 0.129 0.503 
0.102 0.240 0.050 0.144 0.050 0.024 0.116 0.072 0.227 0.069 0.511 
0.168 0.095 0.158 0.070 0.095 0.247 0.014 0.103 0.062 0.235 0.019 
0.140 0.192 0.043 0.123 0.002 0.028 0.465 0.382 0.036 0.238 0.578 
0.094 0.381 0.057 0.294 0.142 0.247 0.084 0.591 0.036 0.011 0.379 
0.128 0.255 0.084 0.199 0.024 0.019 0.065 0.223 0.187 0.074 0.175 
0.045 0.169 0.018 0.147 0.014 0.052 0.032 0.075 0.073 0.007 0.212 
0.190 0.465 0.138 0.388 0.152 0.212 0.168 0.400 0.030 0.121 0.562 
0.065 0.190 0.043 0.121 0.055 0.089 0.001 0.278 0.026 0.043 0.647 
0.156 0.258 0.127 0.199 0.276 0.086 0.014 0.133 0.116 0.013 0.030 
0.062 0.245 0.042 0.136 0.024 0.083 0.150 0.021 0.079 0.042 0.375 
0.492 0.395 0.381 0.289 0.717 0.145 1.532 0.520 0.635 0.119 0.113 
0.064 0.360 0.035 0.227 0.045 0.002 0.158 0.140 0.038 0.088 0.251 
3.2 SPRINT trials 
Similarly the patients that were on the SPRINT protocol were simulated using both 
simulation methods. Table 3 below shows the statistics of the relative error between the 
two methods of a random selection of the 51 patients. Similarly to the patients in the 17 
patient ICU cohort the errors are very minimal. Table 4 below shows similar statistics but 
for the whole cohort. 
Table 3: Statistics of SPRINT patients 
Lower Upper Lower Upper 
Patient Mean Median quartile Quartile 90%CI 90%CI 
2 0.188118 0.184593 0.132298 0.235058 0.268436 0.168518 
20 0.15563 0.150717 0.126189 0.186866 0.126653 0.183414 
35 0.155091 0.140964 0.17444 0.241625 0.106719 0.094491 
43 0.32469 0.279172 0.375171 0.267716 0.717453 0.281026 
46 0.234352 0.209837 0.204789 0.253927 0.133744 0.307065 
Table 4: Statistics of whole SPRINT cohort 
Upper 
90% 
Cl 
Bolus 
0.338 
0.110 
0.506 
1.017 
0.253 
0.328 
0.063 
0.366 
0.106 
0.032 
0.155 
0.160 
0.212 
0.096 
0.194 
0.024 
0.030 
Lower Upper Lower Upper 
Patient Mean Median quartile Quartile 90%CI 90%CI 
Total 
cohort 0.232189 0.196952 0.259557 0.438311 0.386066 0.276299 
4 Discussion and Conclusions 
The concept of "Model-based Therapeutics" and the importance of fast forward 
simulation for enabling the rigorous testing of protocols was introduced in this paper. 
For a non-linear glucose-insulin model an analytical solution was created by 
exploiting structure and partial solutions in a subset of model and writing in terms of 
integrable functions in physiological ranges. The key idea was to taylor the solutions 
to the specific application which was the rapid calculation of glucose values only on 
the hour given bolus, infusion and feed inputs. The current method uses a numerical 
solution which computes the glucose at every small time step within the hour 
dramatically slowing down simulation speed and hindering the number of protocols 
etc that could be tested. 
The analytical approach gave speed increases 6000 times faster than the current 
numerically based approach and very accurate solutions were found with means 
typically around 0.1% and a standard deviation similar. This has already had a 
significant impact on the ability to develop improved SPRINT protocols as tum 
around time has been massively improved. 
Future work will look at extending and applying the concept in this paper to other 
areas of bio-medical engineering, in particular, cardiac modelling and insulin 
sensitivity testing. Note that the most fundamental aspect of the approach is the 
highly efficient storing and manipulation of data based on knowledge of the structure 
as compared to a black box interpolation based look up table which would require 
huge numbers of data points to store and be very computationally expensive. 
Another way of looking at the approach in this paper is that the partial solutions found 
are invariant expressions with respect to the varying inputs, in this case infusion, 
bolus and feeds. By separating parts of the model which have generalizable solutions 
with respect to these inputs, dramatic computational savings can be obtained. The 
solutions themselves represent invariants in the respect that their structure (e.g. 
always a LambertW function structure) remains the same no matter what the input. 
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